Exabis Library
Welcome to the e-CCO Library!
P412: Evolution of patients with ulcerative colitis who withdraw the maintenance treatment with mesalazine
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P412: The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P412: Time trend in clinicopathological features and prognosis of Ulcerative Colitis associated neoplasia: A nationwide cohort in Japan
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P412: White cell count (WCC) and mean corpuscular volume (MCV) as surrogate markers for thiopurine monitoring in inflammatory bowel disease (IBD) treatment: A single-centre experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P413 General impressions about nutrition in patients with inflammatory bowel disease using a nutritional survey
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P413: A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P413: Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b2 vaccines in the immunosuppressed (RESCUE)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P413: Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn`s disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P413: Endoscopic balloon dilatation of Crohn’s strictures is safe and effective in selected cases
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P413: Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P413: Relative frequency of relapses in patients with ulcerative colitis and Crohn's disease treated with mesenchymal stromal cells: Five-years of follow-up
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P413: Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P414 Risk factors for the development of anti-drug antibodies to infliximab and adalimumab in Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P414: Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P414: Loss of response to anti-TNF in inflammatory bowel disease in a Portuguese centre
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P414: Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P414: Stoma in patiens with IBD: friend or foe? -\tEffect of stoma on course of disease, psychological well-being and working capacity
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P414: Usefulness of ultrasonography in the assessment of postoperative recurrence of Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P414: Ustekinumab endoscopic response at Week 16 is associated with early normalisation of faecal calprotectin after induction
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P414: Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM